4.5 Review

Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: Focus on the actions of cannabinoids

期刊

EUROPEAN JOURNAL OF NEUROSCIENCE
卷 55, 期 4, 页码 1032-1050

出版社

WILEY
DOI: 10.1111/ejn.14712

关键词

burning mouth syndrome; cannabinoids; cannabis; endocannabinoid system; hormonal; immunological; neuropathic orofacial pain; psychological; therapeutics

资金

  1. Enterprise Ireland [IP/2018/0740]

向作者/读者索取更多资源

Burning mouth syndrome (BMS) is a neuropathic pain disorder characterized by a burning sensation on oral mucosal surfaces, along with xerostomia, dysgeusia, and tingling or paraesthetic sensations. The classification of the disorder has posed a diagnostic challenge for clinicians/dentists. Recent research has provided insights into the pathophysiological mechanisms and therapeutic strategies for BMS, but controlled clinical studies are needed to support the effectiveness of these approaches. The potential of cannabis-based therapeutics in managing BMS patients is also explored.
Burning mouth syndrome (BMS) is a neuropathic pain disorder associated with a burning sensation on oral mucosal surfaces with frequently reported xerostomia, dysgeusia and tingling or paraesthetic sensations. However, patients present no clinically evident causative lesions. The poor classification of the disorder has resulted in a diagnostic challenge, particularly for the clinician/dentist evaluating these individuals. Major research developments have been made in the BMS field in recent years to address this concern, principally in terms of the pathophysiological mechanisms underlying the disorder, in addition to therapeutic advancements. For the purpose of this review, an update on the pathophysiological mechanisms will be discussed from a neuropathic, immunological, hormonal and psychological perspective. This review will also focus on the many therapeutic strategies that have been explored for BMS, including antidepressants/antipsychotics, non-steroidal anti-inflammatories, hormone replacement therapies, phytotherapeutic compounds and non-pharmacological interventions, overall highlighting the lack of controlled clinical studies to support the effectiveness of such therapeutic avenues. Particular focus is given to the cannabinoid system and the potential of cannabis-based therapeutics in managing BMS patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据